Nykode Therapeutics AS 2023 SR
The report highlights Nykode Therapeutics' ESG performance for 2023, focusing on its transition toward CSRD and ESRS compliance. Key achievements include maintaining a diverse workforce with 68% female staff and advancing clinical trials for groundbreaking drugs while adhering to ethical standards. The company reported a significant increase in Scope 3 emissions due to expanded data accounting for purchased goods. Nykode also emphasized its commitment to a sustainable supply chain and human rights due diligence in alignment with the Norwegian Transparency Act.
Company: Nykode Therapeutics AS
Sector: Professional & technical services
Country: Norway
Year: 2023
Type: SR
Pages: 16
Back to company
Nykode Therapeutics AS
ESG Report
The report highlights Nykode Therapeutics' ESG performance for 2023, focusing on its transition toward CSRD and ESRS compliance. Key achievements include maintaining a diverse workforce with 68% female staff and advancing clinical trials for groundbreaking drugs while adhering to ethical standards. The company reported a significant increase in Scope 3 emissions due to expanded data accounting for purchased goods. Nykode also emphasized its commitment to a sustainable supply chain and human rights due diligence in alignment with the Norwegian Transparency Act.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Apr 1, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Total Waste
Women on Board
Women in Management
Employees